RGEN
REPLIGEN CORP
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$180.17
+1.83%Year over year
Reported trailing growth
- Revenue
- +16.5%
- EBITDA
- +61.5%
- EBIT
- +373.7%
- EPS
- +825.0%
- Free cash flow
- +4.6%
- Operating cash flow
- +2.1%
Forward estimates
Based on analyst estimates
- Revenue
- +19.5%
- EBITDA
- +49.9%
- EPS
- +228.3%
Three-year CAGR
- Revenue
- -2.7%
- EBITDA
- -13.0%
- EBIT
- -35.8%
- Net income
- -35.9%
- EPS
- -36.2%
- Free cash flow
- +34.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026